AI-guided structural modeling and proteomics identified molecular glues that degrade VAV1, a potential target in blood cancers and autoimmune diseases.
Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...
Consortium members are expected to have access to the dataset by early 2027, and there are plans to add more complex antibody ...
The findings by scientists at NYU Abu Dhabi provide new insight into how cells respond when cancer-causing genes are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results